Soverini et al. retrospectively analyzed Ph + ALL patients treated with dasatinib by cloning the BCR-ABL kinase domain in a bacterial vector and sequencing 200 independent clones per sample. This evidence concerns the gene BCR and acute lymphoblastic leukemia.